Updated Jan. 5, 2018 Among the most successful medical device companies of 2017, there were two themes: innovation and breadth of services. That was the major takeaway of an MDO analysis of the stock performance of the 100 largest publicly traded medtech companies in the world. What does innovation mean? Think Align Technology (Nasdaq:ALGN) and […]
Bruker Corp. (NSDQ:BRKR) said today it inked a deal to pick up Oncovision‘s preclinical imaging business for an undisclosed amount. Oncovision will retain its clinical human imaging business, including its Mammi PET breast cancer diagnostic tool, the companies said. “With this planned acquisition, Bruker expects to strengthen its expertise and leadership in preclinical imaging. The […]
Bayer (ETR:BAYN) named strategy chief Werner Baumann to replace Marijn Dekkers as CEO today, prompting some industry watchers to speculate that there’s more deal-making ahead for the German firm’s non-pharma markets. Baumann, who’s slated to succeed Dekkers May 1, joined Bayer in 1988 and made a name for himself with the successful integration of rival drugmaker […]
Baxter (NYSE:BAX) said today that it named Boston Scientific (NYSE:BSX) CEO Mike Mahoney to its board of directors. Mahoney, who engineered a significant turnaround at Boston Scientific, was tapped to serve on Baxter’s governance and compensation committees. “Mike’s significant knowledge of the global medical products business and his track record of leadership will make a significant contribution […]
(Reuters) — A former Wells Fargo trader yesterday was cleared of insider trading charges brought by the U.S. Securities & Exchange Commission, after a major appellate decision limited authorities’ ability to pursue such cases. Following a trial before the regulator’s in-house court, Administrative Law Judge Jason Patil dismissed the charges against Joseph Ruggieri, who the SEC said […]
December 16, 2014 by Brad Perriello
Bruker Corp. (NSDQ:BRKR) shares took a double-digit dive this morning after the medical device company said it expects the European fiscal crisis to cut its 2ns-quarter per-share earnings roughly in half.
Bruker said it expects to report adjusted EPS of 11¢-13¢ for the 3 months ended June 30, on sales of about $420 million. Wall Street analysts were expecting adjusted EPS of 21¢.